Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719877 | 0.95 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL5447212 | 0.95 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL19001727 | 0.95 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL221064 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL222877 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL221063 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL25213322 | 0.91 | GPR119 (0.58) | CYP2D6GPR119MMP13KMT2ASTS | |
| SCHEMBL3155904 | 0.89 | GPR119 (0.55) | CYP2D6GPR119MMP13STS | |
| SCHEMBL1875061 | 0.89 | GPR119 (0.56) | GPR119MMP13KMT2ASTSMEN1 | |
| SCHEMBL31651612 | 0.89 | GPR119 (0.55) | CYP2D6GPR119MMP13KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1277737-A1 | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1256575-A1 | PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0278621-B1 | SUBSTITUTED AMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRL1 | CYP2D6 456/4885GPR119 124/4885MMP13 4342/4885 |
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM5 | CYP2D6 1386/4885GPR119 325/4885MMP13 4371/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | CYP2D6 3220/4885GPR119 1993/4885MMP13 3680/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | CYP2D6 957/4885GPR119 1556/4885MMP13 669/4885 |
| US-20030171370-A1 | Phenoxyalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRD1 | CYP2D6 658/4885GPR119 173/4885MMP13 3625/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | CYP2D6 2788/4885GPR119 812/4885MMP13 4870/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | CYP2D6 2173/4885GPR119 4409/4885MMP13 63/4885 |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | CYP2D6 701/4885GPR119 141/4885MMP13 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.